LILRB4 and in situ carcinoma: Regarding the percentage of ILT3 positive cells, CIS patients tended to have higher numbers of ILT3+CD14+ cells (mean +/-S.E.M.: 55.03+/−5.85; p<0.05) compared to RRMS patients (34.78 +/−5.73) and healthy controls (25.54 +/−4.16).